Sonnet BioTherapeutics (SONN) Short Interest Ratio & Short Volume → This 1 Biotech Stock has been shocking the markets (From Huge Alerts) (Ad) Free SONN Stock Alerts Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Sonnet BioTherapeutics Short Interest DataCurrent Short Volume424,200 sharesPrevious Short Volume452,200 sharesChange Vs. Previous Month-6.19%Dollar Volume Sold Short$767,802.00Short Interest Ratio / Days to Cover4.3Last Record DateApril 15, 2024Outstanding Shares3,070,000 sharesFloat Size2,780,000 sharesShort Percent of Float15.26%Today's Trading Volume6,441 sharesAverage Trading Volume79,936 sharesToday's Volume Vs. Average8% Short Selling Sonnet BioTherapeutics ? Sign up to receive the latest short interest report for Sonnet BioTherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatSONN Short Interest Over TimeSONN Days to Cover Over TimeSONN Percentage of Float Shorted Over Time Ad Porter & CompanyHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.Click here to watch this now before it’s too late. Sonnet BioTherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/2024424,200 shares $767,802.00 -6.2%15.3%4.3 $1.81 3/31/2024452,200 shares $841,092.00 -18.9%16.3%4.5 $1.86 3/15/2024557,500 shares $1.13 million +119.4%20.1%5.1 $2.02 2/29/2024254,100 shares $500,577.00 +9.5%9.1%2.5 $1.97 2/15/2024232,100 shares $378,323.00 +38.8%8.4%4.7 $1.63 1/31/2024167,200 shares $244,112.00 +2.0%6.0%3 $1.46 Get the Latest News and Ratings for SONN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Sonnet BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/2024163,900 shares $219,626.00 +44.5%5.9%2.2 $1.34 12/31/2023113,400 shares $197,316.00 +21.2%4.1%1.5 $1.74 12/15/202393,600 shares $131,976.00 +49.5%3.4%1.3 $1.41 11/30/202362,600 shares $87,014.00 +18.1%2.4%0.9 $1.39 11/15/202353,000 shares $68,900.00 -11.5%2.0%0.7 $1.30 10/31/202359,900 shares $74,276.00 +24.5%2.5%0.7 $1.24 10/15/202348,100 shares $111,592.00 -9.3%3.3%0.7 $2.32 9/30/202353,000 shares $151,845.00 +59.6%3.7%0.7 $2.87 9/15/202333,200 shares $119,520.00 -1.2%2.3%0.4 $3.60 8/31/202333,600 shares $147,840.00 -94.1%2.3%0.3 $4.40 8/15/2023570,500 shares $186,610.55 +59.9%N/A0.1 $0.33 7/31/2023356,700 shares $118,638.42 -39.4%N/A0.1 $0.33 7/15/2023588,400 shares $255,306.76 -19.4%N/A0.1 $0.43 6/30/2023729,900 shares $357,651.00 -64.2%N/A0.2 $0.49 6/15/20232,040,000 shares $1.90 million -24.2%13.6%0.5 $0.93 5/31/20232,690,000 shares $1.38 million +441.9%15.7%0.9 $0.51 5/15/2023496,400 shares $111,044.68 -46.1%2.8%0.3 $0.22 4/30/2023921,700 shares $220,747.15 +255.7%5.0%0.9 $0.24 4/15/2023259,100 shares $94,571.50 +115.4%1.3%0.3 $0.37 3/31/2023120,300 shares $43,308.00 -45.2%0.6%0.2 $0.36 3/15/2023219,500 shares $122,963.90 -41.0%1.1%0.4 $0.56 2/28/2023372,200 shares $314,397.34 -30.7%1.9%0.8 $0.84 2/15/2023536,700 shares $520,545.33 +197.5%2.8%1.1 $0.97 1/31/2023180,400 shares $207,460.00 -46.7%2.4%0.2 $1.15 1/15/2023338,700 shares $477,567.00 +154.7%4.5%0.1 $1.41 12/30/2022133,000 shares $152,950.00 +830.1%1.8%0 $1.15 12/15/202214,300 shares $13,871.00 -96.0%0.2%0 $0.97 11/30/2022359,900 shares $359,900.00 +11.7%8.7%0.1 $1.00 11/15/2022322,300 shares $393,206.00 +125.4%7.8%0.1 $1.22 10/31/2022143,000 shares $275,990.00 -15.8%3.5%0 $1.93 10/15/2022169,800 shares $212,250.00 -74.0%4.1%0.5 $1.25 9/30/2022652,200 shares $958,734.00 +1,427.4%15.7%1.9 $1.47 9/15/202242,700 shares $135,700.60 -88.3%1.0%0.1 $3.18 8/31/2022363,800 shares $76,834.56 +52.7%N/A0.3 $0.21348 million Americans lives to END as we know it? (Ad)348 million American lives are about to change FOREVER.... Because thanks to one shocking A.I. development I'm revealing for the first time today...To see my free research, simply click here now. SONN Short Interest - Frequently Asked Questions What is Sonnet BioTherapeutics' current short interest? Short interest is the volume of Sonnet BioTherapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 424,200 shares of SONN short. 15.26% of Sonnet BioTherapeutics' shares are currently sold short. Learn More on Sonnet BioTherapeutics' current short interest. What is a good short interest ratio for Sonnet BioTherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SONN shares currently have a short interest ratio of 4.0. Learn More on Sonnet BioTherapeutics's short interest ratio. What is a good short interest percentage for Sonnet BioTherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 15.26% of Sonnet BioTherapeutics' floating shares are currently sold short. Is Sonnet BioTherapeutics' short interest increasing or decreasing? Sonnet BioTherapeutics saw a decline in short interest in April. As of April 15th, there was short interest totaling 424,200 shares, a decline of 6.2% from the previous total of 452,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Sonnet BioTherapeutics' float size? Sonnet BioTherapeutics currently has issued a total of 3,070,000 shares. Some of Sonnet BioTherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Sonnet BioTherapeutics currently has a public float of 2,780,000 shares. How does Sonnet BioTherapeutics' short interest compare to its competitors? 15.26% of Sonnet BioTherapeutics' shares are currently sold short. Here is how the short interest of companies compare to Sonnet BioTherapeutics: TFF Pharmaceuticals, Inc. (2.77%), Protagenic Therapeutics, Inc. (0.28%), Cingulate Inc. (0.58%), First Wave BioPharma, Inc. (2.05%), Genprex, Inc. (2.69%), Hoth Therapeutics, Inc. (3.39%), Synaptogenix, Inc. (3.21%), Xenetic Biosciences Inc (0.22%), Kintara Therapeutics, Inc. (1.79%), Oragenics, Inc. (2.07%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Sonnet BioTherapeutics stock? Short selling SONN is an investing strategy that aims to generate trading profit from Sonnet BioTherapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Sonnet BioTherapeutics? A short squeeze for Sonnet BioTherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SONN, which in turn drives the price of the stock up even further. How often is Sonnet BioTherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SONN, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: TFF Pharmaceuticals Short Squeeze Protagenic Therapeutics Short Squeeze Cingulate Short Squeeze First Wave BioPharma Short Squeeze Genprex Short Squeeze Hoth Therapeutics Short Squeeze Synaptogenix Short Squeeze Xenetic Biosciences Short Squeeze Kintara Therapeutics Short Squeeze Oragenics Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SONN) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDems have chosen Biden replacement?Paradigm PressThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithUrgent Nvidia WarningAltimetryTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange